Actionable news
All posts from Actionable news
Actionable news in ACAD: ACADIA Pharmaceuticals Inc.,

Investors Await Pricing of Acadia's Recently Approved Parkinson's Drug


Investors in Acadia Pharmaceuticals (ACAD - Get Report) will eye the pricing of the company's recently approved drug for the treatment of hallucinations and delusions in Parkinson's disease patients, which received FDA approval on Friday.

Acadia has yet to set the price for the drug, but in a Monday morning call with analysts said it would give guidance on the price "shortly."

Acadia's share price initially spiked to 7%, from $32.40 to $34.90 after the Friday announcement, but dropped Monday after Acadia held a morning call with analysts about Nuplazid. The stock closed at $33 per share, dropping 5.4% from the initial Monday morning spike.

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks with serious upside potential. See them FREE for 14-days.

The bio-pharmaceutical company, which operates in San Diego, Calif., plans to sell Nuplazid, which is the first drug of its kind, as soon as next month. The company has hired 132 representatives to market the drug across the...